Correlation Between Gut Microbiota and Tumor Immune Microenvironment: A Bibliometric and Visualized Study

Overview

Journal World J Clin Oncol

Publisher Baishideng Publishing Group

Specialty Oncology

Date 2025 Feb 25

PMID 39995564

Authors

Zheng-Jun Hu

Hui-Rong Zhu

Yong-Jie Jin

Pan Liu

Xiao-Wei Yu

Yu-Ren Zhang

Affiliations

Soon will be listed here.

Abstract

Background: In recent years, numerous reports have been published regarding the relationship between the gut microbiota and the tumor immune microenvironment (TIME). However, to date, no systematic study has been conducted on the relationship between gut microbiota and the TIME using bibliometric methods.

Aim: To describe the current global research status on the correlation between gut microbiota and the TIME, and to identify the most influential countries, research institutions, researchers, and research hotspots related to this topic.

Methods: We searched for all literature related to gut microbiota and TIME published from January 1, 2014, to May 28, 2024, in the Web of Science Core Collection database. We then conducted a bibliometric analysis and created visual maps of the published literature on countries, institutions, authors, keywords, references, using CiteSpace (6.2R6), VOSviewer (1.6.20), and bibliometrics (based on R 4.3.2).

Results: In total, 491 documents were included, with a rapid increase in the number of publications starting in 2019. The country with the highest number of publications was China, followed by the United States. Germany has the highest number of citations in literature. From a centrality perspective, the United States has the highest influence in this field. The institutions with the highest number of publications were Shanghai Jiao Tong University and Zhejiang University. However, the institution with the most citations was the United States National Cancer Institute. Among authors, Professor Giorgio Trinchieri from the National Institutes of Health has the most local impact in this field. The most cited author was Fan XZ. The results of journal publications showed that the top three journals with the highest number of published papers were and The three most frequently used keywords were gut microbiota, tumor microenvironment, and immunotherapy.

Conclusion: This study systematically elaborates on the research progress related to gut microbiota and TIME over the past decade. Research results indicate that the number of publications has rapidly increased since 2019, with research hotspots including "gut microbiota", "tumor microenvironment" and "immunotherapy". Exploring the effects of specific gut microbiota or derived metabolites on the behavior of immune cells in the TIME, regulating the secretion of immune molecules, and influencing immunotherapy are research hotspots and future research directions.

References

Inamura K . Gut microbiota contributes towards immunomodulation against cancer: New frontiers in precision cancer therapeutics. Semin Cancer Biol. 2020; 70:11-23. DOI: 10.1016/j.semcancer.2020.06.006. View

Pushalkar S, Hundeyin M, Daley D, Zambirinis C, Kurz E, Mishra A . The Pancreatic Cancer Microbiome Promotes Oncogenesis by Induction of Innate and Adaptive Immune Suppression. Cancer Discov. 2018; 8(4):403-416. PMC: 6225783. DOI: 10.1158/2159-8290.CD-17-1134. View

Riquelme E, Zhang Y, Zhang L, Montiel M, Zoltan M, Dong W . Tumor Microbiome Diversity and Composition Influence Pancreatic Cancer Outcomes. Cell. 2019; 178(4):795-806.e12. PMC: 7288240. DOI: 10.1016/j.cell.2019.07.008. View

Dodson M . Citation analysis: Maintenance of h-index and use of e-index. Biochem Biophys Res Commun. 2009; 387(4):625-6. DOI: 10.1016/j.bbrc.2009.07.091. View

Wang N, Rong W, Xie Y, Chen S, Xi Z, Deng R . Visualizing the bibliometrics of the inflammatory mechanisms in intervertebral disc degeneration. Exp Gerontol. 2024; 188:112380. DOI: 10.1016/j.exger.2024.112380. View

Lv B, Wang Y, Ma D, Cheng W, Liu J, Yong T . Immunotherapy: Reshape the Tumor Immune Microenvironment. Front Immunol. 2022; 13:844142. PMC: 9299092. DOI: 10.3389/fimmu.2022.844142. View

Goldszmid R, Dzutsev A, Viaud S, Zitvogel L, Restifo N, Trinchieri G . Microbiota modulation of myeloid cells in cancer therapy. Cancer Immunol Res. 2015; 3(2):103-9. PMC: 4324508. DOI: 10.1158/2326-6066.CIR-14-0225. View

Yang C, Yeh Y, Yu H, Chin C, Hsu C, Liu H . Oral Microbiota Community Dynamics Associated With Oral Squamous Cell Carcinoma Staging. Front Microbiol. 2018; 9:862. PMC: 5943489. DOI: 10.3389/fmicb.2018.00862. View

Guillot N, Romeo B, Manesh S, Milano G, Brest P, Zitvogel L . Manipulating the gut and tumor microbiota for immune checkpoint inhibitor therapy: from dream to reality. Trends Mol Med. 2023; 29(11):897-911. DOI: 10.1016/j.molmed.2023.08.004. View

10.

Jin C, Lagoudas G, Zhao C, Bullman S, Bhutkar A, Hu B . Commensal Microbiota Promote Lung Cancer Development via γδ T Cells. Cell. 2019; 176(5):998-1013.e16. PMC: 6691977. DOI: 10.1016/j.cell.2018.12.040. View

11.

Zhang B, Jin Z, Zhai T, Ding Q, Yang H, Wang J . Global research trends on the links between the gut microbiota and diabetes between 2001 and 2021: A bibliometrics and visualized study. Front Microbiol. 2022; 13:1011050. PMC: 9557185. DOI: 10.3389/fmicb.2022.1011050. View

12.

Ahn J, Chen C, Hayes R . Oral microbiome and oral and gastrointestinal cancer risk. Cancer Causes Control. 2012; 23(3):399-404. PMC: 3767140. DOI: 10.1007/s10552-011-9892-7. View

13.

Leinwand J, Miller G . Microbes as biomarkers and targets in pancreatic cancer. Nat Rev Clin Oncol. 2019; 16(11):665-666. DOI: 10.1038/s41571-019-0276-3. View

14.

Flemer B, Warren R, Barrett M, Cisek K, Das A, Jeffery I . The oral microbiota in colorectal cancer is distinctive and predictive. Gut. 2017; 67(8):1454-1463. PMC: 6204958. DOI: 10.1136/gutjnl-2017-314814. View

15.

Luu M, Schutz B, Lauth M, Visekruna A . The Impact of Gut Microbiota-Derived Metabolites on the Tumor Immune Microenvironment. Cancers (Basel). 2023; 15(5). PMC: 10001145. DOI: 10.3390/cancers15051588. View

16.

Brennan C, Garrett W . Fusobacterium nucleatum - symbiont, opportunist and oncobacterium. Nat Rev Microbiol. 2018; 17(3):156-166. PMC: 6589823. DOI: 10.1038/s41579-018-0129-6. View

17.

Park E, Chelvanambi M, Bhutiani N, Kroemer G, Zitvogel L, Wargo J . Targeting the gut and tumor microbiota in cancer. Nat Med. 2022; 28(4):690-703. DOI: 10.1038/s41591-022-01779-2. View

18.

Locy H, de Mey S, de Mey W, De Ridder M, Thielemans K, Maenhout S . Immunomodulation of the Tumor Microenvironment: Turn Foe Into Friend. Front Immunol. 2019; 9:2909. PMC: 6297829. DOI: 10.3389/fimmu.2018.02909. View

19.

Luu M, Riester Z, Baldrich A, Reichardt N, Yuille S, Busetti A . Microbial short-chain fatty acids modulate CD8 T cell responses and improve adoptive immunotherapy for cancer. Nat Commun. 2021; 12(1):4077. PMC: 8249424. DOI: 10.1038/s41467-021-24331-1. View

20.

Tanoue T, Morita S, Plichta D, Skelly A, Suda W, Sugiura Y . A defined commensal consortium elicits CD8 T cells and anti-cancer immunity. Nature. 2019; 565(7741):600-605. DOI: 10.1038/s41586-019-0878-z. View